A*STAR Bioprocessing Technology Institute (A*STAR BTI)

Multidisciplinary efforts across A*STAR are paving the way toward Singapore’s precision medicine vision.

A*STAR researchers discover a mechanism that fires up the metabolism of cancer-killing immune cells, paving the way for future cancer immunotherapies.

Scientists create a platform for reliably customising antibody molecular structures, opening the door to more potent and effective antibody medicines.

Ushering in an era of targeted precision medicine, scientists across A*STAR are propelling the research, commercialisation and implementation of RNA-based therapeutics.

Supported by A*STAR in the early days of their budding careers, scholars recount the experiences that opened the doors to bigger successes from academia to public service.

A new streamlined method for purifying lab-grown viruses could accelerate vaccine production, allowing manufacturers to respond rapidly to emerging viral threats

From music streaming technology to COVID-19 tests, A*STAR Assistant Chief Executive (Enterprise) Sze Wee Tan details how the agency is bringing their innovations out of the lab and into the real world.

Through the years, A*STAR has always stood at the forefront of science and technology and innovation. Here’s how A*STAR came to be and what it has in store in the upcoming decades.

Using whole-exome sequencing, scientists have identified a gene likely linked to a common eye disorder that can lead to blindness in the elderly.

A*STAR researchers have created the first machine learning model for predicting clinical outcomes of stem cell therapies in patients with cartilage disorders.

A newly-discovered role for an immune regulator in T cells may help unravel the molecular basis of inflammatory bowel disease and serve as a promising therapeutic target.

Using a large-scale siRNA screen and CRISPR-Cas9 technology, researchers have pinpointed genes that can enhance antibody production in Chinese hamster ovary cells.